News

The pharmaceutical industry is highly competitive, and currently, the leading company in the sector is likely Eli Lilly (NYSE: LLY). That's driven by the fact that Eli Lilly makes the weight loss

The past few years have been a challenging ride for Pfizer (NYSE: PFE). Since the company made history in 2022, when it became the first in the biopharma industry to reach $100 billion in annual

An analyst's price target increase for UnitedHealth Group (NYSE: UNH) stock was taken to heart by investors on Wednesday. Following news of the boost, they collectively pushed the large health insur

For years, UnitedHealth Group (NYSE: UNH) has been one of the best growth stocks to own on the New York Stock Exchange. A leading health insurance company, it generated solid and continuous growth

UnitedHealth (NYSE: UNH) stock is testing the patience of investors.

*Stock prices used were the afternoon prices of Nov. 28, 2025. The video was published on Nov. 30, 2025.

Continue reading

Source

New investing trends pop up on Wall Street all the time. Over the past seven years, we have witnessed excitement surrounding cannabis stocks, the metaverse, artificial intelligence, and more

The U.S. healthcare industry has been a lightning rod for controversy for years, but it's especially murky right now.

A political battle continues within the U.S. government over renewing expired

Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) are two of the largest and most respected pharmaceutical companies in the world. If you are looking to buy high-quality companies, they should

Healthcare has been a painful industry to invest in this year. Rising claims usage and overall medical costs have sent expenses soaring for insurers such as UnitedHealth Group, whose stock is now

Shares of the pharmaceutical giant Pfizer (NYSE: PFE) have suffered over the last three years, falling some 50% since December 2022. Shares have been weighed down by the collapse in revenue from its

While few investors have successfully timed the markets, buy-and-hold strategies tend to yield favorable results over the long term. The key is to select well-run companies that make highly

Billionaire David Tepper's Appaloosa hedge fund has 45 holdings. That's large enough to be diversified. However, it's still small enough that it matters significantly which individual stocks and

The words "Ozempic" and "Wegovy" almost have become household names as these products have changed the lives of many – from our own friends and family to celebrities. These drugs, prescribed for

You may have noticed that the markets are exceptionally volatile at the moment. That's true whether we're talking about stocks, cryptocurrencies, or commodities.

During turbulent times, many

This year hasn't been the easiest for UnitedHealth Group (NYSE: UNH). The biggest U.S. health insurer has faced several challenges, from the unexpected departure of its chief executive officer back

The past five years have been a roller-coaster ride for Pfizer (NYSE: PFE). The pharmaceutical giant shook up its business -- for instance, by getting rid of its off-patent drug unit -- and made a

Healthcare giant Pfizer (NYSE: PFE) has been offering a high yield for some time. But that hasn't been enough to get investors to buy up the stock. You can see that in its sluggish share price, and

The obesity drug market is creating trillion-dollar winners, but you don't have to pay premium prices for exposure. Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) are both relatively

Despite some volatility earlier in the year, 2025 has shaped up to be another impressive year for artificial intelligence (AI) stocks. Per usual, data analytics platform Palantir Technologies

Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predicted to grow rapidly in the next decade

The healthcare sector is a highly competitive, highly regulated, and technically complex industry. Which is why most investors should probably stick to the industry's largest companies.

With a

The last five or six years have been a roller-coaster ride for Pfizer (NYSE: PFE) and its shareholders. It was a fun ride on the way up, but after peaking in late 2021, the pharmaceutical giant's

Pfizer (NYSE: PFE) has been southbound for the past three years. Following its success in the coronavirus market, which made it the first company in the biopharma industry to generate $100 billion

Merck (NYSE: MRK) has a $210 billion market cap. Pfizer (NYSE: PFE) has a market cap of $135 billion. They are both pharmaceutical industry giants with long and successful histories behind them. But

As an old investing adage goes: Investors have lost more reaching for yield than at the point of a gun. That may sound a bit dramatic, but when you think of all the yield trap stocks -- high-yield